Skip to Content

Biotest AG BIO

Morningstar Rating
€41.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BIO is trading within a range we consider fairly valued.
Price
€40.88
Fair Value
€65.52
Uncertainty
Very High
1-Star Price
€622.76
5-Star Price
€87.12
Economic Moat
Lszrcz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIO is a good fit for your portfolio.

Trading Information

Previous Close Price
€41.00
Day Range
€40.6041.00
52-Week Range
€39.6044.00
Bid/Ask
€0.00 / €0.00
Market Cap
€1.62 Bil
Volume/Avg
742 / 73

Key Statistics

Price/Earnings (Normalized)
8.33
Price/Sales
2.02
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
2,426

Comparables

Valuation

Metric
BIO
VVY
NYKD
Price/Earnings (Normalized)
8.33
Price/Book Value
3.072.152.88
Price/Sales
2.0241.59
Price/Cash Flow
8.92
Price/Earnings
BIO
VVY
NYKD

Financial Strength

Metric
BIO
VVY
NYKD
Quick Ratio
0.889.148.43
Current Ratio
2.049.378.43
Interest Coverage
5.92−517.82
Quick Ratio
BIO
VVY
NYKD

Profitability

Metric
BIO
VVY
NYKD
Return on Assets (Normalized)
13.98%−67.58%−18.26%
Return on Equity (Normalized)
41.79%−77.07%−23.64%
Return on Invested Capital (Normalized)
19.73%−78.19%−26.98%
Return on Assets
BIO
VVY
NYKD
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
BtvzwrmbHlqkvc$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
VwnqtnzhSkcrvb$114.2 Bil
Moderna Inc
MRNA
DjxcjyqLyjf$53.7 Bil
argenx SE ADR
ARGX
PlpgrchkQmbmn$23.0 Bil
BioNTech SE ADR
BNTX
MmzzbcwcqFtdy$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
DmmbhxxqtGlcmpkm$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
JpldgbfqGkhcg$15.9 Bil
United Therapeutics Corp
UTHR
NcskzksvPmbpf$12.8 Bil
Incyte Corp
INCY
RdwdqtzRlqrrd$12.2 Bil
Royalty Pharma PLC Class A
RPRX
FrwnrvtrcfBvzwyps$12.2 Bil

Sponsor Center